Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20093 + HRS-5041
- Development stage
- Phase 1
- Lead developer
- Shanghai Hansoh Biomedical
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
HS-20093 + HRS-5041 is an investigational combination therapy for advanced prostate cancer. HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) that targets B7-H3, a membrane protein highly expressed on various solid tumor cells, including prostate cancer. The ADC is composed of an anti-B7-H3 monoclonal antibody linked to a topoisomerase I inhibitor payload, aiming to deliver cytotoxic agents directly to tumor cells and induce cell death. HRS-5041 is a small molecule proteolysis-targeting chimera (PROTAC) that selectively degrades the androgen receptor, disrupting androgen receptor-driven signaling central to prostate cancer progression. The combination is under investigation in a phase Ib clinical trial for safety, tolerability, and pharmacokinetics in patients with advanced prostate cancer who have progressed on prior standard therapies.
02
Targets
AR (Adrenergic receptors)B7-H3
Beyond the preview
Go deeper on HS-20093 + HRS-5041.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20093 + HRS-5041.